A Research Guide for
Depression & Anxiety

It is worth saying plainly, because so many people carry the opposite belief: depression and anxiety are real medical conditions involving the brain and body, not character flaws, weakness, or something you should be able to “snap out of.” Decades of research show measurable changes in brain circuits, stress hormones, and inflammation; strong genetic and environmental contributions; and — most importantly — high rates of recovery with proper treatment. Blaming yourself for having depression makes about as much sense as blaming yourself for having asthma or diabetes. This reframing matters practically, because shame and self-blame are among the biggest barriers to seeking help, and seeking help early leads to better outcomes.

A related point is that these conditions are extraordinarily common — depression and anxiety together affect a large fraction of people at some point in life — so you are not alone, and effective treatments exist precisely because so much effort has gone into understanding them. Most people with depression or anxiety improve substantially with treatment, and many recover fully. The goal of modern care is not just to take the edge off but to get you genuinely well.

If you take one idea from this guide, let it be that asking for help is a sign of strength and good sense, not failure — and that the odds are firmly on the side of feeling better. The rest of this guide is about how that happens: how the conditions are diagnosed, what treatments work, how to participate actively in your care, and where to turn in a crisis.

Everyone feels sad, worried, or stressed sometimes, so a fair question is when ordinary distress becomes something worth treating. A few practical markers help. The first is duration and persistence: feeling down for a day or two after a setback is normal; feeling low, hopeless, or anxious most of the day, nearly every day, for two weeks or more is a signal. The second is function: when symptoms start interfering with your work, relationships, sleep, appetite, or ability to enjoy things you used to, that crosses from a rough patch into treatable illness. The third is loss of pleasure (anhedonia) — when activities and people that used to bring joy feel flat — which is a hallmark of depression distinct from ordinary sadness.

You do not need to be at rock bottom to deserve help, and waiting for things to get “bad enough” is a common mistake — earlier treatment generally works better and faster. If you are unsure, a free screening questionnaire (the PHQ-9 for depression or GAD-7 for anxiety, available online) gives a rough sense of severity, and talking to your primary care clinician is a low-stakes first step; you don't need a referral or a diagnosis to start the conversation.

Certain symptoms warrant prompt help regardless of duration: thoughts of suicide or self-harm, inability to function or care for yourself, or symptoms following a traumatic event. And trust the people around you — if loved ones are expressing concern about changes in you, that outside perspective is worth taking seriously, because depression and anxiety can distort our own sense of how we are doing.

At your visits you will likely be asked to fill out short questionnaires — most commonly the PHQ-9 for depression and the GAD-7 for anxiety — and understanding them helps you be an active partner rather than a passive recipient. These are simple, validated checklists that turn how you have been feeling over the past two weeks into a number, and that number does real work: it establishes a starting point, tracks whether treatment is helping, and catches stalls that a single conversation might miss (our memories of “how the last few weeks went” are surprisingly unreliable).

The scores have rough bands — for the PHQ-9, under 5 is minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, and 20+ severe — and the trend over time matters more than any single value. A useful rule your clinician may use: if your score hasn't dropped by about a fifth after four weeks on a treatment, it is a signal to adjust rather than wait indefinitely. The target is not just “better” but remission — a score back in the minimal range — because lingering symptoms are the strongest predictor of relapse.

You can use these tools yourself. Filling out a PHQ-9 or GAD-7 every few weeks (many are free online) gives you and your clinician a shared, honest picture of progress, makes it easier to advocate for a change when something isn't working, and turns treatment into a collaboration with measurable goals rather than a guessing game.

Many people are surprised to learn that depression and anxiety are not separate, unrelated problems — they overlap enormously, frequently occur together, and respond to many of the same treatments. Roughly half of people with depression also have significant anxiety, and vice versa; they share genetic roots, brain pathways, and risk factors. This is why this guide covers them together, and why the same first-line medications (SSRIs and SNRIs) and the same core therapy (CBT) treat both. If you have been diagnosed with one and recognize features of the other, that is common, not contradictory.

Understanding the difference still matters for getting the right help. Depression is centered on low mood, loss of interest or pleasure, and a sense of heaviness, hopelessness, or numbness — the world feels gray and effortful. Anxiety is centered on excessive worry, fear, and a body stuck in “alarm mode” — racing thoughts, restlessness, a pounding heart, and a sense of impending threat. Many people swing between the two or feel both at once: keyed-up and exhausted, worried and hopeless together.

The practical implication is reassuring: you do not need to perfectly sort out which is “primary” to start getting better, because the foundational treatments help both. What matters is describing your actual experience to your clinician — the worry, the low mood, the physical symptoms, the sleep, the thoughts — so the plan can be tailored. And certain specific patterns (panic attacks, trauma-related symptoms, obsessions and compulsions) do point toward specific, highly effective treatments, which is why the details you share are worth getting on the table.

Two conditions in the anxiety family are worth recognizing specifically, because they are often missed, frequently misunderstood, and respond to particular treatments that differ from general anxiety care. PTSD (post-traumatic stress disorder) can follow any overwhelming or life-threatening experience — not only combat — and shows up as intrusive memories or nightmares, avoidance of reminders, feeling constantly on guard, and negative shifts in mood and thinking. It is not weakness or “not getting over it”; it is a recognizable condition, and the most effective treatments are specific trauma-focused therapies (such as CPT, prolonged exposure, and EMDR) that help the brain process the memory. If you have survived trauma and these symptoms persist beyond a month, it is worth seeking a clinician trained in these approaches.

OCD (obsessive-compulsive disorder) is widely misused as a synonym for tidiness, but the real condition is distressing: unwanted, intrusive thoughts, urges, or images (obsessions) that drive repetitive behaviors or mental rituals (compulsions) performed to relieve the anxiety. People with OCD usually know the thoughts are irrational, which adds shame and secrecy — many suffer for years before disclosing them. The crucial point is that OCD has a specific, highly effective treatment: a form of therapy called exposure and response prevention (ERP), often combined with higher-dose SSRIs. Ordinary “talk therapy” and reassurance can actually make OCD worse, which is why getting the right kind of therapy matters so much.

For both conditions, the message is hopeful and specific: they are real, common, and treatable, and they respond best to targeted approaches — so naming what you are experiencing to a knowledgeable clinician is the key that unlocks the treatment that actually works.

Doctors use standardized criteria (DSM-5-TR) along with validated screening tools:

• PHQ-9 (Patient Health Questionnaire-9) — Nine questions that screen for depression severity. Scores: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe. Used at every visit to track progress.
• GAD-7 (Generalized Anxiety Disorder-7) — Seven questions for anxiety severity. Scores: 0–4 minimal, 5–9 mild, 10–14 moderate, 15–21 severe.
• Columbia Suicide Severity Rating Scale (C-SSRS) — Structured questions about suicidal thoughts and behavior, used to assess immediate risk.
• PCL-5 — A 20-item checklist for PTSD symptoms, aligned with DSM-5 criteria.
• Y-BOCS (Yale-Brown Obsessive Compulsive Scale) — Measures OCD severity for both obsessions and compulsions.

Measurement-based care means using these tools at every visit — not just once. If your PHQ-9 score is not dropping by at least 20% after 4 weeks of treatment, it may be time to adjust the plan.

Depression and anxiety involve multiple brain systems, not just “low serotonin.” The old “chemical imbalance” theory was an oversimplification. Current science points to:

• Neurotransmitter imbalance. Serotonin, norepinephrine, dopamine, GABA, and glutamate are all involved to varying degrees. Different medications target different systems.
• Neural circuit dysfunction. The prefrontal cortex (thinking, planning), amygdala (fear center), hippocampus (memory), and anterior cingulate cortex (emotional regulation) communicate abnormally in depression and anxiety.
• Neuroinflammation. Elevated inflammatory markers (IL-6, TNF-alpha, CRP) are found in a subset of depressed patients. This is why anti-inflammatory approaches are being researched.
• HPA axis dysregulation. The stress hormone system (cortisol) is often overactive, contributing to anxiety, sleep problems, and impaired neuroplasticity.
• Reduced neuroplasticity. The brain’s ability to form new connections is impaired. Treatments like antidepressants, ketamine, psilocybin, and exercise all appear to restore neuroplasticity through different pathways.

Understanding these mechanisms helps explain why different treatments work for different people, and why combining approaches (medication that corrects neurotransmitter function plus therapy that retrains neural circuits) is so effective.

Before attributing symptoms solely to a mental health condition, thorough medical evaluation should consider:

• Hypothyroidism — Fatigue, weight gain, low mood, cognitive slowing. A simple TSH blood test rules this out.
• Anemia and vitamin deficiencies — Low B12, folate, vitamin D, and iron can all cause fatigue and depression-like symptoms.
• Sleep apnea — Disrupted sleep causes daytime fatigue, irritability, and cognitive problems that mimic depression. Common and underdiagnosed.
• Chronic pain conditions — Pain and depression share neural pathways. Treating one often helps the other.
• Substance use — Alcohol (a depressant), cannabis (can worsen anxiety), and stimulant withdrawal all produce mood symptoms.
• Medications — Some blood pressure medications (beta-blockers), corticosteroids, hormonal contraceptives, and others can cause depression as a side effect.
• Autoimmune and neurological conditions — Lupus, MS, Parkinson’s disease, and others frequently co-occur with depression.

• Have medical causes of my symptoms been ruled out (thyroid, vitamin levels, sleep apnea)?
• What screening tools are you using to measure my depression or anxiety, and what is my score?
• Will you check my score at each visit so we can track whether treatment is working?
• Do I have one condition or several overlapping ones (e.g., depression plus PTSD, anxiety plus OCD)?
• Could any of my current medications be contributing to my symptoms?
• Have you considered whether I might have bipolar disorder?

The most important thing to understand about starting treatment is the timeline, because mismatched expectations cause many people to give up just before they would have improved. Antidepressants typically take four to six weeks at the right dose to show their full effect, and it is common for mild side effects (nausea, restlessness, sleep changes) to appear in the first days — before the benefits — and then settle. Knowing this in advance helps you push through the early weeks rather than concluding too soon that “it isn't working.” Therapy, too, builds over a course of sessions rather than fixing things in one or two.

A second expectation worth setting: finding the right treatment is often a process of adjustment, not a single perfect choice. The first medication helps many people, but if it doesn't work well enough or causes bothersome side effects, that is normal and expected — there are many alternatives, and switching or adding a second approach helps a large share of people who didn't respond to the first. This is not failure; it is how the system is designed to work, and persistence pays off (with systematic trial-and-adjustment, most people eventually reach remission).

The practical takeaways: give a treatment a fair trial at the right dose before judging it, report side effects rather than silently stopping (your clinician can usually help), keep your follow-up appointments especially in the first couple of months, and combine medication with therapy when your depression or anxiety is more than mild — the combination works better than either alone.

A few practical things about antidepressants prevent the most common problems and frustrations. First, side effects usually come before benefits and often fade: nausea, headache, or jitteriness in the first week or two commonly settle as your body adjusts, so it is worth riding them out (or asking about taking the dose with food or at a different time) rather than stopping immediately. If a side effect is severe or doesn't improve, tell your clinician — switching is easy and there are many alternatives.

Second, sexual side effects are common, treatable, and worth raising — reduced desire or difficulty with arousal or orgasm affects many people on SSRIs/SNRIs, and because it is embarrassing, it often goes unmentioned and quietly drives people to quit. There are real solutions: dose adjustment, switching to a medication less likely to cause this (bupropion, mirtazapine, vortioxetine), adding a counter-agent, or timing strategies. Don't suffer in silence or stop on your own; ask.

Third, and most important for safety: do not stop an antidepressant abruptly. Suddenly stopping — especially short-acting ones like paroxetine or venlafaxine — can cause a temporary but unpleasant discontinuation syndrome (dizziness, flu-like feelings, “brain zaps,” irritability, vivid dreams). This is not addiction; it is a withdrawal-like effect avoided by tapering slowly with your clinician's guidance. When the time comes to stop (usually after 6–12 months of feeling well, sometimes longer for recurrent depression), it is done gradually and on a plan. And if you ever feel suddenly worse, more agitated, or develop thoughts of self-harm after starting or changing a dose — especially if you are under 25 — contact your clinician promptly; close monitoring in the first weeks is routine and protective.

A handful of persistent myths about antidepressants keep people from treatment that could help them, and they are worth addressing directly. “They're addictive.” Antidepressants are not addictive the way opioids or benzodiazepines are — you don't crave them, develop a high, or need ever-escalating doses. They can cause a temporary discontinuation reaction if stopped abruptly (avoided by tapering), but that is a withdrawal-like effect, not addiction. “They'll change my personality” or “make me a zombie.” Well-matched treatment should help you feel more like yourself, not less — if a medication leaves you emotionally numb or flat, that is a side effect to report and adjust, not the goal of treatment.

“I should be able to handle this without medication.” Depression and anxiety are medical conditions, not willpower failures, and taking medication for them is no more a moral weakness than taking insulin for diabetes. “Once I start, I'll be on them forever.” Many people take an antidepressant for a defined period (often 6–12 months after recovery from a first episode) and then taper off successfully; longer-term treatment is a choice reserved for those with recurrent illness, made together with a clinician.

“They don't really work — it's just placebo.” For mild depression the medication-placebo gap is small, which is why therapy and lifestyle are first-line there; but for moderate-to-severe depression and anxiety, the benefit over placebo is real and clinically meaningful. The honest summary is that antidepressants are neither miracle cures nor sugar pills — they are effective medical treatments that work best matched to the right person, at the right dose, alongside therapy and lifestyle change.

Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the most commonly prescribed first-line antidepressants. They work by increasing the availability of serotonin (and norepinephrine for SNRIs) in the brain.

What to expect:

• Benefits typically begin at 2–4 weeks and reach full effect at 6–8 weeks.
• Side effects (nausea, headache, jitteriness) often peak in the first week and then diminish.
• Sexual side effects (reduced desire, difficulty with orgasm) affect 30–60% of people and may persist. This is the most common reason people stop their medication.
• Do not stop abruptly. Discontinuation syndrome (dizziness, “brain zaps,” irritability, flu-like symptoms) can occur. Taper slowly under medical guidance.

Benzodiazepines (alprazolam/Xanax, lorazepam/Ativan, clonazepam/Klonopin, diazepam/Valium) work quickly for anxiety and panic but carry serious risks:

• They work fast — relief within 30–60 minutes. This makes them useful for acute panic or short-term crisis situations.
• Physical dependence develops quickly — often within 2–4 weeks of daily use. Stopping abruptly can cause seizures.
• They impair memory and coordination — increased fall risk (especially in older adults) and driving impairment.
• They can worsen depression — as CNS depressants, they may deepen depressive symptoms.
• They interact dangerously with alcohol and opioids — combined respiratory depression can be fatal.

Bottom line: Benzodiazepines have a role for short-term use (days to a few weeks) while waiting for an SSRI/SNRI to take effect, or for occasional severe panic. They should not be a long-term primary treatment for anxiety. If you have been taking them daily for more than a few weeks, do not stop on your own — a supervised, gradual taper is essential.

If your first antidepressant produces a partial response (some improvement but not remission), your doctor may augment rather than switch. Common evidence-based strategies include:

• Aripiprazole (Abilify) — Low-dose atypical antipsychotic augmentation. FDA-approved for MDD augmentation. Risk: akathisia (restlessness), weight gain.
• Brexpiprazole (Rexulti) — Similar to aripiprazole with possibly lower akathisia risk.
• Cariprazine (Vraylar) — FDA-approved December 2022 for MDD augmentation. Atypical antipsychotic; akathisia is the most common side effect.
• Lumateperone (Caplyta) — FDA-approved November 2025 for MDD augmentation. Novel mechanism affecting serotonin, dopamine, and glutamate. Lower metabolic and weight side effects than older options.
• Quetiapine XR (Seroquel XR) — Atypical antipsychotic approved for MDD augmentation. Sedating; metabolic side effects.
• Lithium — One of the oldest and most evidence-based augmentation strategies. Requires blood level monitoring. Also reduces suicide risk.
• Thyroid hormone (T3) — Liothyronine 25–50 mcg/day has evidence for augmentation even in patients with normal thyroid function.
• Buspirone — Can augment SSRI/SNRI for anxiety and may help with sexual side effects.
• Combination antidepressants — SSRI + bupropion or SSRI + mirtazapine are commonly used combinations.

Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) are older medications that remain important options, especially when newer treatments fail:

• TCAs (amitriptyline, nortriptyline, clomipramine): Effective but have more side effects (dry mouth, constipation, sedation, weight gain, heart conduction changes). Clomipramine is particularly effective for OCD. Dangerous in overdose.
• MAOIs (phenelzine/Nardil, tranylcypromine/Parnate): Highly effective for atypical depression and treatment-resistant cases. Require dietary restrictions (avoiding tyramine-rich foods like aged cheese, cured meats, and tap beer to prevent dangerous blood pressure spikes). Many drug interactions.

These are not first-line treatments, but they should not be forgotten. For some patients, a TCA or MAOI is the medication that finally works.

Not all therapy is the same. Evidence-based psychotherapies have been tested in rigorous clinical trials. Matching the therapy to your condition matters:

Key point: Therapy is not just “talking about your feelings.” Evidence-based therapy involves structured techniques, homework between sessions, and measurable goals. If your therapist does not name the approach they are using, ask.

If your first medication or therapy doesn't bring you all the way to feeling well, that is common and expected — and importantly, it is not the end of the road. Roughly a third of people reach full remission on the first antidepressant; for the rest, the standard, evidence-based next steps work for many more. Your clinician will usually do one of three things: optimize (increase the dose, or give it more time), switch (try a different medication, sometimes from a different class), or augment (add a second medication or therapy to boost the first). With this systematic trial-and-adjustment, the majority of people eventually get well — persistence genuinely pays off.

The key is to treat “not better yet” as information rather than failure. Tell your clinician specifically what has and hasn't changed, and whether side effects are the problem; that guides whether to switch or augment. Adding therapy to medication (or vice versa) is one of the most effective moves, and so is addressing things that quietly block progress — undiagnosed bipolar disorder, thyroid problems, sleep apnea, alcohol use, or ongoing severe stress.

For depression that resists several treatments, there are now genuinely new options that work differently and often faster than traditional antidepressants. Esketamine (a nasal spray given in a monitored clinic) and IV ketamine can lift severe depression within hours to days and are options for treatment-resistant depression and acute crises. TMS (non-invasive magnetic stimulation, done in brief outpatient sessions) and, for the most severe or urgent cases, ECT (still the most effective treatment available) are well established. And psilocybin-assisted therapy is advancing through late-stage trials. If you have tried several treatments without success, ask specifically about referral to a specialist or a treatment-resistant-depression program — these options exist precisely for you.

It helps to know what “recovery” actually means and how to protect it, because depression and anxiety are often recurring conditions — manageable, but worth guarding against return. The goal of treatment is remission: not just feeling somewhat better, but getting back to your baseline self, with symptoms minimal or gone and function restored. Settling for “a bit better” is a common trap, because lingering symptoms are the strongest predictor of relapse — so it is worth working with your clinician until you are genuinely well, not just less unwell.

Once you are well, the question becomes how long to continue treatment. For a first episode, antidepressants are usually continued for at least 6–12 months after you feel better (stopping too early is a leading cause of relapse), and for people with several past episodes, longer-term or indefinite treatment may be wise. Therapy — especially CBT and mindfulness-based approaches — has a lasting protective effect that outlasts the sessions, which is one reason it is so valuable. When you do stop medication, do it gradually and on a plan, and ideally not during a high-stress period.

Relapse prevention is also about recognizing your personal early warning signs — the specific changes (sleep slipping, withdrawing from people, returning worry, loss of interest) that tend to precede a downturn for you — and having a plan to act early, much as an asthma action plan works. Maintaining the basics (sleep, exercise, social connection, limiting alcohol), keeping periodic check-ins even when well, and reaching out promptly when warning signs appear turn recovery into something durable. Many people have one episode and never another; others manage a recurring condition successfully for life. Both are real recovery.

Transcranial Magnetic Stimulation (TMS)

TMS uses magnetic pulses to stimulate specific brain areas (usually the left dorsolateral prefrontal cortex). FDA-cleared for depression that has not responded to at least one antidepressant.

• Standard TMS: 20–30 sessions over 4–6 weeks. Response rates: 50–60%. Non-invasive; no anesthesia needed. Main side effect: mild scalp discomfort.
• Theta Burst Stimulation (TBS): Same efficacy in 3-minute sessions (vs. 37 minutes for standard).
• Accelerated TMS (Stanford/SAINT protocol): Condenses treatment into 5 days of intensive stimulation using fMRI-guided targeting. Open-label trial showed ~90% remission (n=21); sham-controlled RCT confirmed 79% vs 13% remission. Being replicated at major centers. A potential game-changer for acute depression.

The Huntsman Mental Health Institute in Utah performs over 4,000 TMS treatments per year with 50–60% response rates.

Electroconvulsive Therapy (ECT)

ECT is the most effective treatment available for severe depression, with response rates of 70–90%. Modern ECT is very different from its historical reputation:

• Performed under brief general anesthesia with muscle relaxation. The patient feels nothing during the procedure.
• Typically 6–12 sessions (3 times per week) for an acute course, followed by maintenance sessions.
• Right unilateral ultrabrief pulse technique significantly reduces cognitive side effects.
• Particularly indicated for: severe or psychotic depression, catatonia, acute suicidality, pregnancy (when medication risks are a concern), and failure of multiple other treatments.
• Side effects include short-term memory impairment (usually resolves within weeks) and headache.

Other Neuromodulation

• Vagus Nerve Stimulation (VNS): Surgically implanted device for chronic treatment-resistant depression. Effects build over months. FDA-approved.
• Deep Brain Stimulation (DBS): Investigational for the most refractory cases. Electrode implanted in specific brain targets. Available only at research centers.

Esketamine (Spravato) Nasal Spray

A paradigm shift for treatment-resistant depression:

• FDA-approved: For TRD (2019), MDD with acute suicidal ideation (2020), and as standalone monotherapy for TRD (January 2025).
• How it works: NMDA receptor modulation that rapidly restores synaptic connections. Works through a fundamentally different mechanism than traditional antidepressants.
• Speed: Significant improvement can be seen within 24 hours to days, compared to 4–6 weeks for SSRIs.
• Administration: Nasal spray given in a certified clinic. You must be monitored for 2 hours after each dose for dissociation, sedation, and blood pressure changes.
• Schedule: Twice weekly for weeks 1–4, then weekly for weeks 5–8, then weekly or every 2 weeks for maintenance.
• REMS program: Can only be administered in certified healthcare settings (not take-home). This is for safety.
• Who qualifies: Adults who have failed two or more adequate antidepressant trials.

IV Ketamine Infusions

• Off-label but widely used for TRD, suicidal ideation, and PTSD.
• Typically 0.5 mg/kg infused over 40 minutes, given 2–3 times per week initially.
• Rapid onset similar to esketamine but requires IV access.
• Not FDA-approved for depression (used off-label). Insurance coverage varies.
• Long-term effects uncertain. Repeated high-dose use may affect bladder and cognition. Use should be monitored by an experienced clinician.

Psilocybin-Assisted Therapy

The most promising emerging treatment for depression. Key facts:

• Two consecutive positive Phase 3 trials (COMP360, Compass Pathways) for treatment-resistant depression.
• A single 25 mg dose with psychological support showed rapid, significant, and durable improvements.
• Rolling FDA application underway. Potential FDA approval in late 2026 or early 2027.
• Australia became the first country to allow prescribing of psilocybin for TRD (July 2023). As of September 2025, 47 patients had been treated with zero serious adverse events.
• Oregon and Colorado have legalized supervised psilocybin use.
• Not yet FDA-approved in the U.S. Available only through clinical trials or state-legalized programs.

Zuranolone (Zurzuvae) for Postpartum Depression

• First oral treatment specifically for postpartum depression (FDA-approved August 2023).
• Taken for just 14 days. Works through GABA-A receptor modulation.
• The broader MDD indication was rejected by the FDA in the U.S., but Japan approved zuranolone for MDD in December 2025.

MDMA-Assisted Therapy for PTSD

• Showed strong Phase 3 results (~67–71% of participants no longer met PTSD criteria in pivotal MAPP1/MAPP2 trials).
• FDA rejected the application in August 2024, citing methodological concerns.
• Additional Phase 3 trials required. No clear resubmission timeline.

Other Emerging Approaches

• Anti-inflammatory agents (minocycline, celecoxib) — targeting neuroinflammation in depression; promising early data.
• Gut-brain axis interventions (psychobiotics) — probiotics targeting the microbiome-mood connection; very early research.
• Digital therapeutics — FDA-cleared apps (Freespira for panic/PTSD) and AI-assisted therapy tools.
• Note: Kappa opioid receptor antagonists (navacaprant, aticaprant) both failed in Phase 3 trials for MDD.

Definition: Failure to respond adequately to at least 2 different antidepressants, each given at an adequate dose for an adequate duration (4–6 weeks).

The escalation pathway:

1. Optimize — Ensure the current medication is at the right dose for long enough. Check adherence.
2. Switch — Try a different antidepressant (within class or cross-class).
3. Augment — Add a second agent (aripiprazole, lithium, lumateperone, bupropion, T3).
4. Esketamine (Spravato) — Now available as standalone therapy for TRD.
5. TMS — Standard or accelerated (SAINT) protocol.
6. ECT — The most effective treatment for severe, refractory depression.
7. Investigational — Clinical trials (psilocybin, DBS), VNS, IV ketamine.

Important: Before concluding that depression is truly treatment-resistant, confirm that bipolar disorder has been ruled out, substance use is addressed, medical conditions are treated, and the patient is actually taking medication as prescribed.

Many people take herbal supplements alongside antidepressants, often without telling their doctor. Some of these interactions are dangerous:

Rule of thumb: Tell every prescriber about every supplement you take. “Natural” does not mean “safe to combine.”

• What are the most common side effects of this medication, and which ones typically improve over time?
• How long should I try this medication before we decide it is not working?
• If this medication causes sexual side effects or weight gain, what alternatives exist?
• Should I be in therapy as well as taking medication? What type would be best for my condition?
• Am I a candidate for esketamine (Spravato) or TMS?
• What does “treatment-resistant depression” mean, and do I meet that definition?
• Are there clinical trials available for newer treatments like psilocybin?
• Can I safely take [supplement name] with my medication?
• How long will I need to stay on medication, and how will we eventually taper off?

It is genuinely true — not a consolation prize — that lifestyle changes treat depression and anxiety, with effects on mild-to-moderate symptoms that rival medication in some studies. The strongest evidence is for exercise: regular aerobic activity (even brisk walking, around 30 minutes most days) has antidepressant effects substantial enough that major guidelines now list it as a first-line treatment for mild depression. The mechanism is real (changes in brain growth factors, inflammation, and stress hormones), and the dose-response is forgiving — some is much better than none, and you do not need a gym or a training plan to benefit.

Sleep is the second pillar, and it runs in both directions: poor sleep worsens mood and anxiety, and depression and anxiety wreck sleep. Treating insomnia directly — ideally with cognitive behavioral therapy for insomnia (CBT-I), which outperforms sleeping pills long-term — often improves the depression itself. Regular sleep and wake times, limiting alcohol (a depressant that fragments sleep), morning light, and reducing late-day screens are concrete, evidence-based levers.

The other reliable levers are social connection (isolation both deepens and is deepened by depression, so scheduled contact and “behavioral activation” — doing meaningful activities even before you feel like it — genuinely help), reducing alcohol and cannabis (both worsen mood and anxiety over time despite short-term relief), and basic nutrition and sunlight. The honest framing: these work best alongside professional treatment for moderate-to-severe illness, not as a replacement that delays it — but they are real medicine, and they are things you can start today.

Depression and anxiety around pregnancy and the year after birth are common, serious, and very treatable — and they deserve special mention because they are so often missed or dismissed as “just hormones” or “normal new-parent stress.” Perinatal depression and anxiety affect roughly one in seven mothers (and a meaningful number of fathers and non-birthing partners too), can begin during pregnancy or any time in the first year, and are different from the short-lived “baby blues” that resolve within about two weeks. Persistent sadness, severe anxiety or intrusive frightening thoughts, inability to sleep even when the baby sleeps, or feeling disconnected from the baby are signals to seek help, not to tough it out.

The most important message is the same one that applies throughout this guide, with extra force here: untreated depression carries real risks — to the parent and the baby — that generally outweigh the risks of treatment. Effective options exist and are used safely in pregnancy and breastfeeding: therapy (which is often first-line), certain antidepressants with good safety track records (sertraline is the usual first choice), and, for severe postpartum depression, a dedicated medication (zuranolone) and other rapid options. Stopping an antidepressant abruptly on discovering pregnancy is usually the riskier choice, not the safer one — these decisions should be made with your clinician, not alone out of fear.

If you are struggling, tell your obstetric provider, midwife, or doctor — screening is recommended at prenatal and postpartum visits precisely because this is so common and so treatable. In a crisis, the 988 line and the maternal mental health hotline (1-833-TLC-MAMA in the US) are available any time. Getting help is one of the most protective things you can do for both yourself and your child.

Alongside longer-term treatment, it helps to have a few concrete skills for the moments when anxiety or panic spikes — tools you can use anywhere, without medication. The fastest-acting are physical, because anxiety lives in the body as much as the mind. Slow breathing — especially making the out-breath longer than the in-breath (for example, in for four, out for six) for a few minutes — directly calms the body's alarm system. Grounding techniques (naming five things you can see, four you can hear, three you can touch) pull attention out of the spiral of worry and back into the present.

For panic specifically, the single most useful piece of knowledge is that a panic attack, however terrifying, is not dangerous and will pass — it peaks within minutes and then subsides on its own. The racing heart and breathlessness are your body's false alarm, not a sign of a heart attack or of losing control. Reminding yourself “this is panic, it will pass, I am not in danger” and riding it out — rather than fleeing the situation, which teaches the brain that the place was dangerous — is the core of how therapy treats panic.

For worry that won't switch off, techniques like scheduling a brief daily “worry time,” writing the worry down, or distinguishing solvable problems (make a plan) from unsolvable ones (practice letting go) reduce its grip. These skills are the everyday core of cognitive behavioral therapy, and they work better with practice — rehearse them when calm so they are available when you are not. They complement, rather than replace, professional treatment for moderate-to-severe anxiety.

The evidence is now strong enough that the CANMAT 2024 guidelines recommend structured exercise as a first-line monotherapy for mild depression:

• Dose: 30–40 minutes of moderate-intensity aerobic exercise, 3–4 times per week, for a minimum of 9 weeks.
• Effect size: Comparable to SSRIs in multiple randomized trials for mild-to-moderate depression.
• Types that work: Walking, jogging, cycling, swimming, resistance training, yoga, and group exercise all show benefits.
• Mechanism: Increases BDNF (brain-derived neurotrophic factor), endorphins, serotonin, and dopamine. Reduces inflammation and cortisol.
• Getting started when you have no motivation: Start absurdly small. Five minutes of walking counts. Behavioral activation principles apply: do it first, motivation follows action.

Sleep disturbance is both a symptom and a cause of depression and anxiety. Improving sleep can directly improve mood:

• CBT for Insomnia (CBT-I) is more effective than sleeping pills in the long term and is the recommended first-line treatment for chronic insomnia.
• Sleep hygiene basics: Consistent wake time (even weekends), dark and cool bedroom, no screens 1 hour before bed, limit caffeine after noon, avoid alcohol as a sleep aid.
• Address sleep apnea: Common, underdiagnosed, and treatable. If you snore loudly, gasp in sleep, or wake unrefreshed despite adequate hours, ask about a sleep study.

What you eat affects your brain. The evidence base for nutritional psychiatry is growing:

• Mediterranean diet: Associated with 25–30% lower risk of developing depression. Rich in fruits, vegetables, whole grains, fish, olive oil, and nuts.
• Omega-3 fatty acids: EPA-dominant supplements (1,000–1,500 mg/day) have modest antidepressant effects as adjunctive therapy.
• Limit processed foods and sugar: High-glycemic diets are associated with increased depression and anxiety symptoms.
• Gut-brain axis: The microbiome communicates with the brain via the vagus nerve and immune system. Probiotic (“psychobiotic”) research is early but promising.
• Key nutrients: B vitamins (B6, B9/folate, B12), vitamin D, magnesium, zinc, and iron deficiency can all worsen or mimic depression. Check levels if symptoms persist despite treatment.

• Mindfulness-Based Stress Reduction (MBSR): 8-week structured program with moderate evidence for anxiety and mild depression.
• Mindfulness-Based Cognitive Therapy (MBCT): Specifically designed to prevent depression relapse. Recommended by NICE for people with 3+ episodes.
• Daily practice: Even 10–15 minutes of mindfulness meditation reduces cortisol and improves emotional regulation.
• Apps: Headspace, Calm, Insight Timer, and other guided meditation apps can help beginners establish a practice.

Social isolation is both a symptom and an accelerant of depression. Breaking the cycle requires deliberate action:

• Behavioral activation: Schedule meaningful activities even when you do not feel like it. Mood follows action, not the other way around.
• Start small: One text to a friend, one 10-minute walk outside, one meal eaten at a table rather than in bed.
• Support groups: NAMI (National Alliance on Mental Illness), DBSA (Depression and Bipolar Support Alliance), and local peer support groups provide connection with others who understand.
• Reduce social media: Excessive passive scrolling is consistently associated with worsened depression and anxiety in research.

Substance use and depression/anxiety are deeply intertwined:

• Alcohol is a CNS depressant. It may temporarily reduce anxiety but worsens depression, disrupts sleep, and interacts dangerously with most psychiatric medications.
• Cannabis can worsen anxiety and panic in many users, particularly high-THC products. Some evidence for CBD alone reducing anxiety at moderate doses, but interactions with CYP enzymes affect medication metabolism.
• Caffeine can worsen anxiety and panic attacks. Consider reducing or eliminating, especially if you have panic disorder.
• If you are using substances to cope, be honest with your treatment team. Dual-diagnosis programs can address both issues simultaneously.

If you are reading this while having thoughts of ending your life, please know two things: these thoughts are a symptom of an illness that is treatable, not a true reflection of your worth or your future, and help is available right now. In the United States, you can call or text 988 (the Suicide and Crisis Lifeline) any time, day or night, to reach a trained counselor — free and confidential. If you are in immediate danger, call 911 or go to an emergency room. You do not have to be “certain” you would act on the thoughts to deserve help; reaching out when thoughts first appear is exactly the right time.

A few things help in the moment. Tell someone — a friend, family member, or clinician — because suicidal thoughts lose some of their power when spoken aloud, and isolation makes them stronger. Put distance between yourself and any means of harm: ask someone to hold medications or firearms, even temporarily, because most suicidal crises are brief, and surviving the acute moment is often the whole battle. If you have a safety plan from a clinician, use it; if you don't, the crisis line can help you make one.

For people supporting someone at risk: ask directly (asking about suicide does not plant the idea — it relieves isolation), take any mention seriously, help remove access to lethal means, and stay with them while connecting them to help. Suicidal feelings, however overwhelming, are almost always temporary and treatable — the goal is to get through the acute crisis safely, because the large majority of people who survive go on to be glad they did.

If someone you love has depression or anxiety, your support genuinely matters — and knowing how to help (and what to avoid) makes a real difference. The most useful things are often the simplest: listen without trying to fix, take the illness seriously rather than minimizing it (“just think positive” or “others have it worse” deepen shame), and remember that depression is an illness affecting motivation and energy, so a loved one's withdrawal or irritability is usually the illness talking, not a reflection of you. Offering specific, concrete help (“I'll drive you to the appointment” or “I'll sit with you while you call”) works better than the open-ended “let me know if you need anything,” which is hard for a depressed person to act on.

Encourage treatment without nagging, and offer to help with the practical barriers — finding a provider, making the first call, going along. At the same time, protect your own wellbeing: supporting someone with a mental illness is draining, and burnout helps no one. Setting kind limits, keeping your own routines and support, and recognizing that you cannot “fix” them or love the illness away are not selfish — they are what make sustained support possible.

Know the warning signs that require urgent action: talk of suicide or of being a burden, giving away possessions, a sudden calm after a period of despair, or access to lethal means in someone at risk. Ask directly about suicidal thoughts (it does not plant the idea), take any sign seriously, help remove access to means, and don't leave them alone — call 988 or emergency services. You don't have to be a therapist; being present, taking it seriously, and helping connect them to professional care is exactly the right role.

• Talking about wanting to die or kill oneself
• Looking for ways to die (searching online, seeking access to firearms or pills)
• Talking about feeling hopeless or having no reason to live
• Talking about being a burden to others
• Increasing use of alcohol or drugs
• Acting anxious, agitated, or reckless
• Withdrawing from family and friends
• Expressing rage or talking about seeking revenge
• Displaying extreme mood swings
• Sudden calmness after a period of deep depression — this can indicate a decision has been made and is a red flag
• Giving away prized possessions

The Stanley-Brown Safety Plan is an evidence-based tool that helps people navigate suicidal crises. Work with your clinician to create one before a crisis occurs. It includes:

1. Warning signs that a crisis is developing (specific to you)
2. Internal coping strategies you can use on your own (distraction, self-soothing)
3. People and social settings that provide distraction and support
4. People you can ask for help (friends, family members, with their phone numbers)
5. Professionals and agencies to contact (therapist, psychiatrist, 988, ER)
6. Making the environment safe (means restriction — removing access to firearms, stockpiled medications)

Means restriction is the single most effective immediate intervention. Putting distance and time between a person in crisis and lethal means saves lives, because most suicidal crises are time-limited.

Recovering from depression or anxiety is rarely a solo project, and assembling the right support around you makes a real difference. Your team might include a primary care clinician (who can start and manage first-line treatment), a therapist (for evidence-based psychotherapy), a psychiatrist or psychiatric nurse practitioner (for complex medication management), and — just as importantly — trusted people in your life. Peer support groups, whether through organizations like NAMI or condition-specific communities, reduce the isolation that fuels these illnesses and offer practical wisdom from people who have been there.

Access barriers are real, and knowing the workarounds helps. If cost or a shortage of providers is a problem, options include community mental health centers and federally qualified health centers (which use sliding-scale fees), telepsychiatry (which has dramatically expanded access, especially in rural areas), employee assistance programs (often free, confidential, short-term counseling through your job), training clinics at universities (lower-cost therapy from supervised trainees), and patient-assistance programs for expensive medications. If you are uninsured or underinsured, ask directly about these — clinicians and clinic social workers can often point you to resources you wouldn't find on your own.

Two practical tips: keep a simple record of what treatments you have tried and how they worked (it saves enormous time when seeing a new provider), and don't let a long wait for a therapist stop you from starting — your primary care clinician can begin treatment while you wait, and crisis lines and digital tools can bridge gaps. The goal is a sustainable support structure, not a perfect one assembled all at once.

Depression and anxiety often collide with work and school, and a few practical points help you protect both your health and your livelihood. First, these conditions can affect concentration, energy, and reliability in ways that are invisible to others and easy to misread as laziness or disengagement — which is itself a source of stress. Recognizing that the difficulty is the illness, not a character flaw, helps you respond with treatment and reasonable adjustments rather than self-blame.

Second, accommodations exist and are often modest. In the United States and many other places, depression and anxiety can qualify as conditions for which you can request reasonable workplace or academic accommodations — flexible deadlines or hours, a quieter workspace, time off for appointments, or a temporary reduced load — usually with documentation from your clinician. Employee assistance programs (EAPs) offer free, confidential short-term counseling and can be a fast, private entry point to help. Students can access disability services and campus counseling centers.

Third, weigh disclosure thoughtfully: you are generally not obligated to share a diagnosis with an employer, and you can request accommodations through HR or occupational health without broadcasting details. The decision is personal and depends on your workplace and relationships. What matters most is not powering through in silence until you burn out: addressing the illness — through treatment, sustainable boundaries, and using available supports — is what protects your long-term ability to work and study, and recovery is the norm with proper care.

• 988 Suicide & Crisis Lifeline: Call or text 988 (24/7). Veterans press 1.
• Crisis Text Line: Text HOME to 741741
• SAMHSA National Helpline: 1-800-662-4357 (treatment referrals)
• International Association for Suicide Prevention: Crisis centers worldwide

• Huntsman Mental Health Institute (HMHI) — 170-bed psychiatric hospital at the University of Utah. Treatment-Resistant Mood Disorder (TRMD) clinic serving 500+ patients per year. TMS program (4,000+ treatments/year, 50–60% response). Esketamine/Spravato clinic. ECT services. Active clinical trials. NNDC Center of Excellence. Phone: 801-583-2500. healthcare.utah.edu/hmhi
• University of Utah Health — Neurosciences — Inpatient and outpatient psychiatry, partial hospitalization, intensive outpatient programs, ECT services. Phone: 801-585-6387.
• Intermountain Health Behavioral Health — Extensive outpatient network across Utah. New behavioral health centers opening (Alta View 56-bed facility June 2026; Taylorsville pediatric facility September 2025). Ketamine-assisted therapy at select locations. Telepsychiatry for rural areas. Phone: 801-442-2000.
• George E. Wahlen VA Medical Center (Salt Lake City) — Comprehensive psychiatric services for veterans, including PTSD programs, substance use treatment, and crisis services. Phone: 801-582-1565.
• NAMI Utah — Education, support groups, and advocacy. namiut.org
• SafeUT App — 24/7 crisis chat and tip line for Utah youth and adults.

• NAMI (National Alliance on Mental Illness): Family-to-Family courses, support groups, HelpLine (1-800-950-6264). nami.org
• DBSA (Depression and Bipolar Support Alliance): Peer-led support groups nationwide. dbsalliance.org
• ADAA (Anxiety & Depression Association of America): Find-a-therapist tool, educational resources. adaa.org
• American Foundation for Suicide Prevention (AFSP): Research, education, advocacy. afsp.org
• IOCDF (International OCD Foundation): Find OCD-specialized therapists and ERP providers. iocdf.org
• PTSD Foundation / National Center for PTSD: Resources for trauma survivors and veterans. ptsd.va.gov
• Postpartum Support International: Support for postpartum depression and anxiety. 1-800-944-4773. postpartum.net

• Europe (NICE/CANMAT model): Stepped care approach starting with guided self-help and therapy before medication. Esketamine approved by EMA for TRD.
• Australia: First country to allow prescribing of psilocybin for TRD (July 2023). Leading digital mental health programs (MindSpot, THIS WAY UP, Black Dog Institute).
• Japan: Zuranolone approved for MDD in December 2025 (broader than the U.S. PPD-only approval). Integration of traditional Morita therapy and Kampo medicine alongside modern psychiatry.
• Brazil/Latin America: Leading ayahuasca research for depression. Randomized trials showing rapid antidepressant effects in TRD. Warning: Ayahuasca is absolutely contraindicated with SSRIs, SNRIs, and MAOIs due to fatal serotonin syndrome risk.
• Global: WHO estimates over 1 billion people worldwide live with a mental health condition. Treatment coverage ranges from 25% in low-income countries to 80% in high-income countries. The treatment gap remains the greatest challenge in global mental health.

Some medications approved outside the United States may appear in international literature or be encountered by patients who travel or have family abroad. These are not available through normal U.S. prescribing channels.

Agomelatine (Valdoxan)

• Mechanism: Melatonergic MT1/MT2 receptor agonist and 5-HT2C receptor antagonist. A unique mechanism distinct from SSRIs/SNRIs.
• Approved in: European Union and Australia for major depressive disorder.
• NOT FDA-approved. U.S. development was abandoned; it is not available in the United States.
• Evidence: Randomized trials show efficacy comparable to SSRIs with a favorable sexual side-effect profile and potential benefits for sleep architecture.
• Important safety requirement: Requires regular liver function monitoring (ALT/AST) before treatment, at weeks 3, 6, 12, and 24, and periodically thereafter. Contraindicated in patients with hepatic impairment.

St. John’s Wort (Hypericum perforatum)

• Regulatory status: Approved in Germany under the Commission E Monographs for mild-to-moderate depression. Widely used across Europe as a first-line option for mild depression. Available over the counter in the U.S. as a dietary supplement (not FDA-regulated as a drug).
• Evidence: Cochrane systematic reviews show efficacy similar to SSRIs for mild-to-moderate depression, with fewer side effects in short-term use.
• MAJOR drug interactions: St. John’s Wort is a potent inducer of CYP3A4 and P-glycoprotein. It significantly reduces the blood levels and effectiveness of:
  • Oral contraceptives (risk of unintended pregnancy)
  • Warfarin (risk of clotting events)
  • Immunosuppressants (cyclosporine, tacrolimus — risk of organ rejection)
  • Antiretrovirals (risk of HIV treatment failure)
  • Some chemotherapy agents
  • Many other medications metabolized by CYP3A4
• Must NEVER be combined with SSRIs, SNRIs, or MAOIs due to the risk of serotonin syndrome, a potentially life-threatening condition.
• Bottom line: Effective for mild depression when used alone and without interacting medications. Dangerous when combined with many common drugs. Always disclose use to every prescriber and pharmacist.

Mountain West & Utah

• Huntsman Mental Health Institute (HMHI) — University of Utah. Treatment-Resistant Mood Disorder (TRMD) clinic, TMS program (4,000+ treatments/year), esketamine/Spravato clinic, ECT services, active clinical trials. NNDC Center of Excellence. Phone: 801-583-2500. healthcare.utah.edu/hmhi
• University of Utah Health — Neurosciences — Comprehensive psychiatric evaluation, pharmacogenomic testing, integrated psychiatry and psychology, research participation opportunities. Phone: 801-585-6387.
• Intermountain Health Behavioral Health — Outpatient network across Utah with ketamine-assisted therapy at select locations, partial hospitalization and intensive outpatient programs, telepsychiatry for rural areas. Phone: 801-442-2000.

US National

• McLean Hospital (Harvard) — Belmont, MA. One of the top-ranked psychiatric hospitals in the U.S. Depression and anxiety treatment programs, TRD clinic, TMS, ECT, residential programs, clinical trials. Phone: 617-855-3141. mcleanhospital.org
• Massachusetts General Hospital Depression Clinical & Research Program — Boston, MA. Leading TRD research, esketamine clinic, accelerated TMS, clinical trials in psychedelic-assisted therapy. Phone: 617-726-2000. massgeneral.org
• Johns Hopkins Mood Disorders Center — Baltimore, MD. Comprehensive mood disorders evaluation, TMS, ECT, psychedelic research (Center for Psychedelic & Consciousness Research). Phone: 410-955-5000. hopkinsmedicine.org
• Mayo Clinic Department of Psychiatry & Psychology — Rochester, MN (also in Arizona and Florida). Comprehensive mood disorders program, TMS, ECT, integrated care model. Phone: 507-284-2511. mayoclinic.org
• UCSF Weill Institute for Neurosciences — Depression Center — San Francisco, CA. TRD program, neuromodulation (TMS, DBS research), clinical trials. Phone: 415-476-7000.
• Menninger Clinic — Houston, TX. Residential and outpatient treatment for complex psychiatric conditions. Phone: 713-275-5000. menningerclinic.org

Veterans

• George E. Wahlen VA Medical Center (Salt Lake City) — Comprehensive psychiatric services, PTSD treatment programs (CPT, PE, EMDR), TMS, esketamine, substance use treatment, and crisis services for enrolled veterans. Phone: 801-582-1565.
• Veterans Crisis Line: Call 988, then press 1. Available 24/7. Chat at veteranscrisisline.net. Text 838255.
• VA PTSD programs: Specialized residential and outpatient PTSD treatment using CPT, PE, and EMDR therapy. National Center for PTSD (research and clinical resources): ptsd.va.gov. Referral through VA primary care or mental health.
• VA TMS and esketamine programs: Available at many VA medical centers nationwide. Ask your VA provider about access to neuromodulation services.

Canada

• Centre for Addiction and Mental Health (CAMH) — Toronto, ON. Canada’s largest mental health teaching hospital. Mood and anxiety disorders clinic, TMS, ECT, psilocybin research, clinical trials. Phone: 416-535-8501. camh.ca
• Royal Ottawa Mental Health Centre — Ottawa, ON. Mood disorders program, TMS, ECT, treatment-resistant depression clinic, clinical research. Phone: 613-722-6521. theroyal.ca
• Douglas Mental Health University Institute (McGill) — Montreal, QC. Mood disorders program, neuromodulation, clinical trials, specialized programs for treatment-resistant depression. Phone: 514-761-6131. douglas.research.mcgill.ca
• UBC Mood Disorders Centre — Vancouver, BC. CANMAT-affiliated. Mood disorders assessment, treatment optimization, research participation. Phone: 604-822-7512.

International

• UK: Maudsley Hospital / South London and Maudsley NHS Foundation Trust (King’s College London) — London. Leading UK center for mood disorders, TRD, neuromodulation, and clinical trials. National Affective Disorders Service. Phone: +44 20 3228 6000. slam.nhs.uk
• Germany: Max Planck Institute of Psychiatry — Munich. World-leading depression and anxiety research, clinical trial access, HPA axis and neuroplasticity research. Phone: +49 89 30622-1.
• Japan: National Center of Neurology and Psychiatry (NCNP) — Tokyo. Japan’s primary psychiatric research institute. TMS, ECT, clinical trials including zuranolone-related research. Phone: +81 42-341-2711.
• Australia: Black Dog Institute — Sydney. Leading mood disorders research and clinical services. Digital mental health programs. Australia’s psilocybin prescribing pathway for TRD (Authorised Prescriber Scheme). Phone: +61 2 9382 4530. blackdoginstitute.org.au

How to Find Specialized Providers

• ERP therapists for OCD: International OCD Foundation (IOCDF) therapist directory — iocdf.org/find-help
• TMS providers: Clinical TMS Society provider directory — clinicaltmssociety.org
• Esketamine (Spravato) REMS-certified clinics: Spravato treatment center locator — spravato.com
• ECT centers: Ask your psychiatrist for a referral; most academic medical centers and large health systems offer ECT.
• EMDR therapists: EMDR International Association therapist directory — emdria.org
• DBT programs: Behavioral Tech (Linehan Institute) clinician directory — behavioraltech.org

Plain-language definitions of terms used throughout this guide.

• Augmentation — adding a second medication to an antidepressant that is producing a partial response, in order to boost its effectiveness. Common augmenting agents include aripiprazole, lithium, and lumateperone.
• C-SSRS (Columbia Suicide Severity Rating Scale) — a structured interview tool used by clinicians to assess the presence and severity of suicidal thoughts and behavior. Often administered at each visit and in emergency settings.
• CBT (Cognitive Behavioral Therapy) — a structured, evidence-based psychotherapy that identifies and changes negative thought patterns and avoidance behaviors. First-line therapy for depression, GAD, panic disorder, and social anxiety.
• CPT (Cognitive Processing Therapy) — a specific type of CBT designed for PTSD. Focuses on challenging unhelpful beliefs about the traumatic event, such as self-blame or beliefs about safety. Typically 12 sessions.
• DBT (Dialectical Behavior Therapy) — a comprehensive therapy originally developed for suicidality and self-harm. Teaches four skill sets: mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness. Used for emotion dysregulation, borderline personality, and chronic suicidality.
• EMDR (Eye Movement Desensitization and Reprocessing) — a therapy for PTSD and trauma that processes disturbing memories through bilateral stimulation (eye movements, tapping, or tones) while the patient recalls the traumatic event. Endorsed by the VA/DoD and WHO for PTSD.
• ERP (Exposure and Response Prevention) — the gold-standard therapy for OCD. The patient is gradually exposed to obsession triggers while refraining from performing compulsive rituals, allowing anxiety to diminish naturally over time.
• Esketamine — a nasal spray (brand name Spravato) derived from ketamine. FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation. Works through NMDA receptor modulation and can produce improvement within hours to days.
• GAD-7 (Generalized Anxiety Disorder-7) — a seven-item self-report questionnaire used to screen for and measure the severity of generalized anxiety. Scores range from 0 to 21 (0–4 minimal, 5–9 mild, 10–14 moderate, 15–21 severe).
• Pharmacogenomics — the study of how a person’s genes affect their response to medications. Pharmacogenomic testing (e.g., GeneSight, Genomind) can identify genetic variations in drug-metabolizing enzymes (CYP2D6, CYP2C19) that may predict whether a patient will metabolize certain antidepressants too slowly, normally, or too quickly. Useful when multiple medications have failed.
• PHQ-9 (Patient Health Questionnaire-9) — a nine-item self-report questionnaire used to screen for and measure the severity of depression. Scores range from 0 to 27 (0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe). Used at each visit to track treatment response.
• REMS (Risk Evaluation and Mitigation Strategy) — an FDA-required safety program for certain high-risk medications. Esketamine (Spravato) has a REMS program requiring administration in a certified healthcare setting with 2-hour post-dose monitoring.
• Serotonin syndrome — a potentially life-threatening condition caused by excessive serotonin activity in the brain. Can occur when serotonergic drugs are combined (e.g., SSRI + St. John’s Wort, SSRI + MAOI). Symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity, and tremor. Requires emergency treatment.
• SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) — a class of antidepressants that block the reabsorption of both serotonin and norepinephrine. Examples: venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine (Pristiq). Particularly useful when depression is accompanied by chronic pain or fatigue.
• SSRI (Selective Serotonin Reuptake Inhibitor) — the most commonly prescribed class of antidepressants. They work by blocking the reabsorption (reuptake) of serotonin in the brain, making more serotonin available. Examples: sertraline (Zoloft), escitalopram (Lexapro), fluoxetine (Prozac). First-line treatment for depression, anxiety, PTSD, OCD, and panic disorder.
• TRD (Treatment-Resistant Depression) — depression that has not responded adequately to at least two different antidepressant medications, each given at an adequate dose for an adequate duration (typically 4–6 weeks). Affects roughly one-third of people with MDD. Treatment options include esketamine, TMS, ECT, augmentation strategies, and investigational therapies.